# Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

> **NCT04410523** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 335 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** CSJ117
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04410523
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-09
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-09-06
- **Target enrollment:** 335 (ACTUAL)
- **Why stopped:** Sponsor Desicion
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04410523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04410523, "Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04410523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*